Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19542970 | 0.80 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1TDP1 | |
| SCHEMBL5514949 | 0.79 | TDP1 (0.68) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL14803500 | 0.79 | TDP1 (0.68) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL554957 | 0.79 | TDP1 (0.68) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL16804567 | 0.78 | ECE1 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3217572 | 0.77 | TDP1 (0.50) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL25682838 | 0.77 | TDP1 (0.50) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL25682832 | 0.77 | TDP1 (0.50) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL14803532 | 0.75 | ECE1 (0.53) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL19919887 | 0.75 | ECE1 (0.53) | SLC1A3SLC1A2SLC1A1TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSTY | 2023-08-31 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | SLC1A3 3693/4885SLC1A2 3008/4885SLC1A1 3675/4885 |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | CD274, PDCD1LG2, PDCD1 | SLC1A3 3683/4885SLC1A2 3869/4885SLC1A1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.